华西虚拟期刊

华西虚拟期刊

查看全文

Proton pump inhibitors (PPIs) and histamine-2-receptor antagonists (H2RAs) are used for gastro-esophageal reflux disease (GERD); however, the clinical evidence for treatment is poor. We evaluated the effectiveness and tolerability of different doses of PPIs, H2RAs and placebo in adults with GERD. Six online databases were searched through September 1, 2016. All related articles were included and combined with a Bayesian network meta-analysis from randomized controlled trials (RCTs). The GRADE systems were employed to assess the main outcome. Ninety-eight RCTs were identified, which included 45,964 participants. Our analysis indicated that the full/standard dose of esomeprazole at 40 mg per day was the most efficient in healing among nine different dosages of PPIs and H2RAs. The main efficacy outcome did not change after adjustments for the area, age, level of disease from endoscopy, year of publication, pharmaceutical industry sponsorship, Intention-to-treat (ITT)/per-protocol (PP), withdrawal rate, pre-set select design bias, single blinded and unblinded studies, study origination in China, study arms that included zero events, inconsistency node or discontinued drug were accounted for in the meta-regressions and sensitivity analyses. This research suggests that the full/standard doses (40 mg per day) of esomeprazole should be recommended as first-line treatments for GERD in adults for short-term therapy.

Key words: GASTROESOPHAGEAL-REFLUX DISEASE; MIXED TREATMENT COMPARISONS; SHORT-TERM TREATMENT; DECISION-MAKING; BARRETTS-ESOPHAGUS; RANDOMIZED-TRIALS; CLINICAL-TRIAL; DOUBLE-BLIND; 40 MG; INCONSISTENCY

引用本文: . . 华西虚拟期刊, 2000, 1(1): -. doi: 10.1038/srep41021 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,